FRANKFURT, Jan 26 (Reuters) - German drugmaker Dermapharm said it would sell shares worth up to around 400 million euros ($497 million) in an initial public offering and list on the Frankfurt stock exchange on Feb. 9.
It set the price range for the IPO at 26 to 30 euros per share, resulting in a total offering of between 350 million and 404 million euros, it said on Friday.
The company is floating around a 25 percent stake and said on Friday that the offering will comprise a total of 13.46 million shares, of which 3.84 million are new shares from a capital increase and 7.86 million are from the family that controls Dermapharm.
In addition, up to 1.76 million shares from the family have been earmarked for over-allotments.($1 = 0.8050 euros)
(Reporting by Maria Sheahan; Editing by Susan Fenton)
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.